Keep pulling the thread on Eli Lilly.
Eli Lilly has trial data suggesting its oral obesity pill is an effective maintenance treatment for patients who have previously used injectable weight-loss drugs, with participants maintaining the majority of their initial weight loss.
In a clinical trial for Eli Lilly's oral obesity maintenance pill, patients who had previously taken Wegovy regained an average of two pounds after one year.
In a clinical trial for Eli Lilly's oral obesity maintenance pill, patients who had previously taken Zepbound regained an average of approximately 11 pounds after one year.
Eli Lilly's oral obesity pill is positioned to serve as a maintenance treatment within the broader weight loss drug market.
The potential use of Eli Lilly's oral drug as a maintenance therapy is expected to boost its market uptake following regulatory approval.
The oral obesity pills from both Novo Nordisk and Eli Lilly have not yet received regulatory approval.
A deal involving President Donald Trump will reportedly price the starting doses of certain oral obesity pills at $150 per month for cash-paying customers on the direct-to-consumer website Trump Rx.